Page last updated: 2024-12-06

sulotroban

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Sulotroban is a potent, selective, and orally available antagonist of the thromboxane A2 (TXA2) receptor. It was initially developed as an antithrombotic agent for the prevention and treatment of cardiovascular diseases. Sulotroban exhibits high affinity for the TXA2 receptor and effectively blocks the binding of TXA2, thereby inhibiting the vasoconstrictive and platelet-aggregating effects of TXA2. Sulotroban has been shown to reduce platelet aggregation and thrombus formation in various animal models. The compound was investigated in clinical trials for the prevention of cardiovascular events, but it did not demonstrate sufficient efficacy to warrant further development. However, its potent and selective TXA2 receptor antagonism makes it a valuable tool for studying the role of TXA2 in various physiological processes. Sulotroban has also been explored as a potential therapeutic agent in conditions such as pulmonary hypertension, stroke, and cancer.'

sulotroban: thromboxane receptor antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID51550
CHEMBL ID8273
SCHEMBL ID34187
MeSH IDM0120889

Synonyms (36)

Synonym
sulotrobanum [latin]
acetic acid, (4-(2-((phenylsulfonyl)amino)ethyl)phenoxy)-
(4-(2-((phenylsulfonyl)amino)ethyl)phenoxy)acetic acid
bm 13177
skf 95587
sk&f 95587
(p-(2-benzenesulfonamidoethyl)phenoxy)acetic acid
bm 13.177
sk&f-95587
bm-13177
D05970
72131-33-0
sulotroban (usan/inn)
PDSP2_000728
sulotroban
PDSP1_000740
CHEMBL8273 ,
bm-13.177
[4-(2-benzenesulfonylamino-ethyl)-phenoxy]-acetic acid (bm 13177)
[4-(2-benzenesulfonylamino-ethyl)-phenoxy]-acetic acid
bdbm50002765
[4-(2-benzenesulfonylamino-ethyl)-phenoxy]-acetic acid(sulotroban)
2-[4-[2-(benzenesulfonamido)ethyl]phenoxy]acetic acid
sulotroban [usan:inn:ban]
unii-74574co5a6
sulotrobanum
74574co5a6 ,
SCHEMBL34187
sulotroban [mart.]
sulotroban [usan]
sulotroban [inn]
DTXSID80222440
4-(2-benzenesulfonylaminoethyl)phenoxyacetic acid
XTNWJMVJVSGKLR-UHFFFAOYSA-N
4-[2-(benzene-sulphonamido)-ethyl]-phenoxyacetic acid
Q27266250

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The plasma and urine concentrations of sulotroban were measured by gas-chromatography over 72 h and the pharmacokinetic parameters were calculated."( Pharmacokinetics of the thromboxane A2 receptor antagonist sulotroban (BM 13.177) in renal failure.
Jumeau-Ziemendorff, Y; Kaufmann, B; Piper, C; Staiger, C; Stein, K; Uebis, V, 1989
)
0.79
" Pharmacodynamic effects were measured ex vivo by the testing of platelet functions such as shape change, aggregation, and [3H]serotonin release."( The pharmacokinetic and pharmacodynamic profiles of the thromboxane A-2 receptor blocker BM 13.177.
Endele, R; Kaufmann, B; Neugebauer, G; Patscheke, H; Staiger, C; Stegmeier, K; Strein, K, 1986
)
0.27
"The pharmacokinetics and pharmacodynamic effect on platelet activation of a single 800 mg oral dose of BM 13."( Single dose pharmacokinetics and effects on platelet function of the thromboxane receptor blocker BM 13.177.
Endele, R; Kaufmann, B; Neugebauer, G; Patscheke, H; Staiger, C; Stegmeier, K; Strein, K, 1986
)
0.27

Compound-Compound Interactions

ExcerptReferenceRelevance
" This study reveals 1) a differential efficacy of TXA2 synthase inhibition, singly or combined with TXA2/prostaglandin endoperoxide receptor antagonism, depending on the extent of the vessel wall lesion triggering thrombosis and the size of the thrombus required to obstruct the vascular lumen and 2) a significant synergism in preventing occlusive thrombosis of extensively damaged coronary arteries between strong TXA2 synthase inhibition and comparatively modest TXA2/prostaglandin endoperoxide receptor antagonism with ridogrel."( Differential effects of thromboxane A2 synthase inhibition, singly or combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on occlusive thrombosis elicited by endothelial cell injury or by deep vascular damage in canine coronary ar
De Clerck, F; Hemans, C; Van Ammel, K; Van de Water, A; Vandeplassche, G; Wouters, L; Xhonneux, R, 1991
)
0.28
"Differential effects on human platelet function of thromboxane A2 (TXA2) synthetase inhibition singly and of TXA2 synthetase inhibition combined with TXA2/prostaglandin endoperoxide receptor antagonism were revealed, using ridogrel as a probe."( Effect of thromboxane A2 synthetase inhibition, singly and combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on inositol phospholipid turnover and on 5-HT release by washed human platelets.
de Chaffoy de Courcelles, D; De Clerck, F, 1990
)
0.28
" High levels of inhibition were associated with an excess of haemorrhagic complications especially in combination with a low plasma fibrinogen level."( A study of the use of the thromboxane A2 antagonist, sulotroban, in combination with streptokinase for local thrombolysis in patients with recent peripheral arterial occlusions: clinical effects, platelet function and fibrinolytic parameters.
Berridge, DC; Heptinstall, S; Hopkinson, BR; Lonsdale, RJ; Makin, GS; Wenham, PW; Westby, JC, 1993
)
0.54

Dosage Studied

ExcerptRelevanceReference
" After administration of SK&F 95587, vasoconstrictor responses to the TXA2 mimics were reduced significantly, and the dose-response curves were shifted to the right in a parallel fashion."( Sulotroban selectively inhibits thromboxane-receptor-mediated responses in the peripheral vascular bed of the cat.
Kadowitz, PJ; Kvamme, P; Minkes, RK, 1992
)
1.73
", dose-response curves for U46619 and U44069 were shifted to the right in a parallel manner."( Blockade of thromboxane/endoperoxide receptor-mediated responses in the pulmonary vascular bed of the cat by sulotroban.
Babycos, CR; Hood, JS; Ibrahim, IN; Kadowitz, PJ; McMahon, TJ; Nossaman, BD; Ragheb, MS, 1992
)
0.5
"0 mg kg-1 min-1 dosage only."( Characterization of the renal effects and renal elimination of sulotroban in the dog.
Cyronak, MJ; Goldstein, RS; Kao, J; Kinter, LB; Mann, WA; Sozio, RS; Welzel, GE, 1991
)
0.52
" The PAF receptor antagonism with BN 50730 was overcome when 10-fold larger doses of PAF were administered and the dose-response curves for changes in lung resistance and dynamic compliance were shifted to the right in a parallel manner."( Influence of SK&F 95587 and BN 50730 on bronchoconstrictor responses in the cat.
Beckerman, RC; Bellan, JA; Braquet, P; Dyson, MC; Kadowitz, PJ; McNamara, DB; Minkes, RK; Wegmann, MJ, 1990
)
0.28
"2 fold rightward shift of the dose-response curve."( Antagonism of PGD2 vasodepressor responses in the rat in vivo by the novel, selective antagonist, BW A868C.
Hamid-Bloomfield, S; Whittle, BJ, 1989
)
0.28
" Selective PAF, TXA2 and 5HT antagonists (WEB 2086, sulotroban and MCI-9042) clearly inhibited both the shape change and the aggregation induced by the appropriate agonist; in each case the effect of the antagonist was to move the dose-response curve to the right."( Studies on the effects of agonists and antagonists on platelet shape change and platelet aggregation in whole blood.
Heptinstall, S; Lösche, W; Sanderson, HM; Vickers, J, 1996
)
0.54
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Thromboxane A2 receptor Homo sapiens (human)Ki1.13750.00061.24073.8040AID210340; AID212256; AID212257
Thromboxane-A synthase Homo sapiens (human)IC50 (µMol)94.10000.00091.230410.0000AID210346
Thromboxane A2 receptorRattus norvegicus (Norway rat)Ki0.65000.65000.65000.6500AID210340
Thromboxane-A synthaseRattus norvegicus (Norway rat)IC50 (µMol)10.00000.00400.39231.5000AID212449; AID212450
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
smooth muscle contractionThromboxane A2 receptor Homo sapiens (human)
G protein-coupled receptor signaling pathwayThromboxane A2 receptor Homo sapiens (human)
response to nutrientThromboxane A2 receptor Homo sapiens (human)
response to xenobiotic stimulusThromboxane A2 receptor Homo sapiens (human)
positive regulation of blood coagulationThromboxane A2 receptor Homo sapiens (human)
response to testosteroneThromboxane A2 receptor Homo sapiens (human)
thromboxane A2 signaling pathwayThromboxane A2 receptor Homo sapiens (human)
response to ethanolThromboxane A2 receptor Homo sapiens (human)
positive regulation of angiogenesisThromboxane A2 receptor Homo sapiens (human)
positive regulation of smooth muscle contractionThromboxane A2 receptor Homo sapiens (human)
cellular response to lipopolysaccharideThromboxane A2 receptor Homo sapiens (human)
negative regulation of cell migration involved in sprouting angiogenesisThromboxane A2 receptor Homo sapiens (human)
inflammatory responseThromboxane A2 receptor Homo sapiens (human)
positive regulation of blood pressureThromboxane A2 receptor Homo sapiens (human)
positive regulation of vasoconstrictionThromboxane A2 receptor Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationThromboxane A2 receptor Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayThromboxane A2 receptor Homo sapiens (human)
prostaglandin biosynthetic processThromboxane-A synthase Homo sapiens (human)
icosanoid metabolic processThromboxane-A synthase Homo sapiens (human)
cyclooxygenase pathwayThromboxane-A synthase Homo sapiens (human)
intracellular chloride ion homeostasisThromboxane-A synthase Homo sapiens (human)
response to ethanolThromboxane-A synthase Homo sapiens (human)
positive regulation of vasoconstrictionThromboxane-A synthase Homo sapiens (human)
response to fatty acidThromboxane-A synthase Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
thromboxane A2 receptor activityThromboxane A2 receptor Homo sapiens (human)
guanyl-nucleotide exchange factor activityThromboxane A2 receptor Homo sapiens (human)
protein bindingThromboxane A2 receptor Homo sapiens (human)
monooxygenase activityThromboxane-A synthase Homo sapiens (human)
thromboxane-A synthase activityThromboxane-A synthase Homo sapiens (human)
iron ion bindingThromboxane-A synthase Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygenThromboxane-A synthase Homo sapiens (human)
heme bindingThromboxane-A synthase Homo sapiens (human)
12-hydroxyheptadecatrienoic acid synthase activityThromboxane-A synthase Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityThromboxane-A synthase Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
acrosomal vesicleThromboxane A2 receptor Homo sapiens (human)
plasma membraneThromboxane A2 receptor Homo sapiens (human)
nuclear speckThromboxane A2 receptor Homo sapiens (human)
plasma membraneThromboxane A2 receptor Homo sapiens (human)
endoplasmic reticulumThromboxane-A synthase Homo sapiens (human)
endoplasmic reticulum membraneThromboxane-A synthase Homo sapiens (human)
cytosolThromboxane-A synthase Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (52)

Assay IDTitleYearJournalArticle
AID179228Inhibition of U-46619 (3x10E-8 M) induced contraction in rat thoracic aorta1993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
Design, synthesis, and pharmacology of 3-substituted sodium azulene-1-sulfonates and related compounds: non-prostanoid thromboxane A2 receptor antagonists.
AID165375Tested for the concentration that causes 50% relaxation when contraction in rabbit aorta was induced by 3 x 10 E -8 M of U-46619.1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Azulene derivatives: new non-prostanoid thromboxane A2 receptor antagonists.
AID76462Inhibitory effect of the compounds on U-46619-induced platelet aggregation ex vivo in guinea pig at the dose of 100 mg/kg 7 hr oral after administration; NT = not tested1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Non-prostanoid thromboxane A2 receptor antagonists with a dibenzoxepin ring system. 1.
AID212450Inhibitory effect against thromboxane A2 synthase binding to bovine platelets1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Non-prostanoid thromboxane A2 receptor antagonists with a dibenzoxepin ring system. 1.
AID167796Compound was tested for the inhibition of U-46619 (3 x10 E -8 M) induced platelet aggregation in rabbit platelet rich plasma1993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
Design, synthesis, and pharmacology of 3-substituted sodium azulene-1-sulfonates and related compounds: non-prostanoid thromboxane A2 receptor antagonists.
AID212118Inhibitory effect against binding thromboxane A2 receptor on guinea pig platelets using [3H]U-46619 as radioligand at 1 uM concentration1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Non-prostanoid thromboxane A2 receptor antagonists with a dibenzoxepin ring system. 1.
AID76867Percent inhibition of increase in pulmonary resistance was measured on arachidonic acid induced bronchoconstriction in the anesthetized guinea pig after 3 min1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Synthesis and pharmacological evaluation of 5,6-exo-epoxy-7-oxabicyclo[2.2.1]heptane derivatives.
AID165374Tested for the concentration that cause 50% inhibition of the maximum aggregation with rabbit platelet-rich plasma induced by 2.5 x 10 E -6 M of U-466191990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Azulene derivatives: new non-prostanoid thromboxane A2 receptor antagonists.
AID167647Antagonist activity against contraction of rabbit aortic strips1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 2. Synthesis and biological activity of 8-(benzenesulfonamido)-7-(3-pyridinyl)octaonic acid and related compounds.
AID179768In vitro inhibitory concentration measured against U-46,619 (30 nM) induced contraction for rat aorta1991Journal of medicinal chemistry, Jun, Volume: 34, Issue:6
FTIR spectral study of intramolecular hydrogen bonding in thromboxane A2 receptor antagonist S-145 and related compounds. 3. Conformation and activity of S-145 analogues.
AID212262Compound was tested for its binding affinity at Thromboxane A2 receptor by measuring its ability to displace [3H]U-46619 from guinea pig platelets1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Non-prostanoid thromboxane A2 receptor antagonists with a dibenzoxepin ring system. 1.
AID179769In vitro inhibitory concentration measured against collagen (4 uML) induced aggregation of washed platelets (WP) in rat1991Journal of medicinal chemistry, Jun, Volume: 34, Issue:6
FTIR spectral study of intramolecular hydrogen bonding in thromboxane A2 receptor antagonist S-145 and related compounds. 3. Conformation and activity of S-145 analogues.
AID231367Ratio of washed platelets to that of platelet rich plasma1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 2. Synthesis and biological activity of 8-(benzenesulfonamido)-7-(3-pyridinyl)octaonic acid and related compounds.
AID167831In vitro inhibitory concentration measured against U-46,619 (1 uM) induced aggregation of washed platelets (WP) in rabbit1991Journal of medicinal chemistry, Jun, Volume: 34, Issue:6
FTIR spectral study of intramolecular hydrogen bonding in thromboxane A2 receptor antagonist S-145 and related compounds. 3. Conformation and activity of S-145 analogues.
AID210346Activity against TXA2 synthase in bovine platelet microsome1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
Dibenzoxepin derivatives: thromboxane A2 synthase inhibition and thromboxane A2 receptor antagonism combined in one molecule.
AID76461Inhibitory effect of the compounds on U-46619-induced platelet aggregation ex vivo in guinea pig at the dose of 100 mg/kg 4 hr after oral administration1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Non-prostanoid thromboxane A2 receptor antagonists with a dibenzoxepin ring system. 1.
AID86596Inhibitory effect on the specific binding of [3H]pyrilamine to guinea pig cerebellum histamine H1 receptor at 1 uM1993Journal of medicinal chemistry, Feb-05, Volume: 36, Issue:3
Dibenz[b,e]oxepin derivatives: novel antiallergic agents possessing thromboxane A2 and histamine H1 dual antagonizing activity. 1.
AID222786Inhibitory activity against U-46,619-induced aggregation of washed human platelets.1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 2. Synthesis and biological activity of 8-(benzenesulfonamido)-7-(3-pyridinyl)octaonic acid and related compounds.
AID232748Selectivity index is the difference between the IC50 values in the aggregation and contraction assays1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Azulene derivatives: new non-prostanoid thromboxane A2 receptor antagonists.
AID210335In vitro for percent inhibition against TXA2 / PGH-2 receptor using [125I]PTA-OH in human platelets at 10 e-5 M1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Synthesis and structure-activity relationships of novel benzimidazole and imidazo[4,5-b]pyridine acid derivatives as thromboxane A2 receptor antagonists.
AID77950Compound was tested ex vivo for it's inhibition of U-46619 induced platelet aggregation in the guinea pig after 2 hr of administration at dose 100 mg/kg1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Non-prostanoid thromboxane A2 receptor antagonists with a dibenzoxepin ring system. 1.
AID253693Negative logarithm of the drug concentration2005Journal of medicinal chemistry, Oct-20, Volume: 48, Issue:21
Designed multiple ligands. An emerging drug discovery paradigm.
AID210340Tested in vitro for inhibition constant against TXA2 / PGH-2 receptor using [125I]PTA-OH binding affinity to human platelets1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Synthesis and structure-activity relationships of novel benzimidazole and imidazo[4,5-b]pyridine acid derivatives as thromboxane A2 receptor antagonists.
AID76868Percent inhibition of increase in pulmonary resistance was measured on arachidonic acid induced bronchoconstriction in the anesthetized guinea pig after 30 min1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Synthesis and pharmacological evaluation of 5,6-exo-epoxy-7-oxabicyclo[2.2.1]heptane derivatives.
AID77960Compound was tested ex vivo for it's inhibition of U-46619 induced platelet aggregation in the guinea pig after 4 hr of administration at dose 30 mg/kg1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Non-prostanoid thromboxane A2 receptor antagonists with a dibenzoxepin ring system. 1.
AID76459Inhibitory effect of the compounds on U-46619-induced platelet aggregation ex vivo in guinea pig at the dose of 10 mg/kg 7 hr oral after administration; NT = not tested1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Non-prostanoid thromboxane A2 receptor antagonists with a dibenzoxepin ring system. 1.
AID77952Compound was tested ex vivo for it's inhibition of U-46619 induced platelet aggregation in the guinea pig after 2 hr of administration at dose 30 mg/kg1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Non-prostanoid thromboxane A2 receptor antagonists with a dibenzoxepin ring system. 1.
AID212261Antagonistic activity against Thromboxane A2 receptor in guinea pig trachea in the presence of 9,11-azo-PGH21990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
9,11-epoxy-9-homoprosta-5-enoic acid analogues as thromboxane A2 receptor antagonists.
AID212453Compound was tested for its inhibitory activity against Thromboxane A2 synthase obtained from bovine platelet microsomes at 10 uM1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Non-prostanoid thromboxane A2 receptor antagonists with a dibenzoxepin ring system. 1.
AID210486Inhibitory effect on the specific binding of [3H]-U-46,619 to guinea pig platelets TXA2 / PGH-2 receptors1993Journal of medicinal chemistry, Feb-05, Volume: 36, Issue:3
Dibenz[b,e]oxepin derivatives: novel antiallergic agents possessing thromboxane A2 and histamine H1 dual antagonizing activity. 1.
AID210488Tested for specific binding of radioligand [3H]U-46619 to thromboxane A2/prostaglandin H2 receptor in guinea pig washed platelets1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
Dibenzoxepin derivatives: thromboxane A2 synthase inhibition and thromboxane A2 receptor antagonism combined in one molecule.
AID212259Compound was tested for its binding affinity at Thromboxane A2 receptor by measuring its ability to displace [3H]-U-46,619 from guinea pig platelets at 1 uM1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Non-prostanoid thromboxane A2 receptor antagonists with a dibenzoxepin ring system. 1.
AID212449Compound was tested for its inhibitory activity against Thromboxane A2 synthase obtained from bovine platelet microsomes1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Non-prostanoid thromboxane A2 receptor antagonists with a dibenzoxepin ring system. 1.
AID76456Inhibitory effect of the compounds on U-46619-induced platelet aggregation ex vivo in guinea pig at the dose of 10 mg/kg 4 hr after oral administration1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Non-prostanoid thromboxane A2 receptor antagonists with a dibenzoxepin ring system. 1.
AID212256Compound was tested for its binding affinity at Thromboxane A2 receptor by measuring its ability to displace [3H]U-46619 from guinea pig platelets at 0.1 uM1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Non-prostanoid thromboxane A2 receptor antagonists with a dibenzoxepin ring system. 1.
AID212116Inhibitory effect against binding thromboxane A2 receptor on guinea pig platelets using [3H]U-46619 as radioligand at 0.1 uM concentration1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Non-prostanoid thromboxane A2 receptor antagonists with a dibenzoxepin ring system. 1.
AID89219Antagonist activity against U-46,619-induced aggregation of platelet rich plasma (PRP)1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 2. Synthesis and biological activity of 8-(benzenesulfonamido)-7-(3-pyridinyl)octaonic acid and related compounds.
AID197113Inhibitory activity against aggregation of rat washed platelets (induced by 4 ug/mL of collagen)1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Synthesis and in vitro activity of stereoisomers of a novel thromboxane receptor antagonist, (+-)-(5Z)-7-[3-endo-[(phenylsulfonyl)amino]bicyclo [2.2.1]hept-2-exo-yl]heptenoic acid.
AID196944Inhibitory activity against rat thoracic aorta(induced by 30 nM of U-46619)1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Synthesis and in vitro activity of stereoisomers of a novel thromboxane receptor antagonist, (+-)-(5Z)-7-[3-endo-[(phenylsulfonyl)amino]bicyclo [2.2.1]hept-2-exo-yl]heptenoic acid.
AID212452Inhibitory effect against thromboxane A2 synthase from bovine platelets at 10 uM concentration1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Non-prostanoid thromboxane A2 receptor antagonists with a dibenzoxepin ring system. 1.
AID210344Antagonist activity against TXA2 receptor measured by inhibition of U-46,619-induced contractions of rat aorta1997Journal of medicinal chemistry, Oct-10, Volume: 40, Issue:21
Thromboxane modulating agents. 3. 1H-imidazol-1-ylalkyl- and 3-pyridinylalkyl-substituted 3-[2-[(arylsulfonyl)amino]ethyl]benzenepropanoic acid derivatives as dual thromboxane synthase inhibitor/thromboxane receptor antagonists.
AID92538Inhibitory activity against aggregation of human platelet-rich plasma(induced by 4 uM of U-46619)1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Synthesis and in vitro activity of stereoisomers of a novel thromboxane receptor antagonist, (+-)-(5Z)-7-[3-endo-[(phenylsulfonyl)amino]bicyclo [2.2.1]hept-2-exo-yl]heptenoic acid.
AID76866Percent inhibition of increase in pulmonary resistance was measured on arachidonic acid induced bronchoconstriction in the anesthetized guinea pig after 10 min1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Synthesis and pharmacological evaluation of 5,6-exo-epoxy-7-oxabicyclo[2.2.1]heptane derivatives.
AID77958Compound was tested ex vivo for it's inhibition of U-46619 induced platelet aggregation in the guinea pig after 4 hr of administration at dose 100 mg/kg1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Non-prostanoid thromboxane A2 receptor antagonists with a dibenzoxepin ring system. 1.
AID76463Inhibitory effect of the compounds on U-46619-induced platelet aggregation ex vivo in guinea pig at the dose of 30 mg/kg 2 hr after oral administration1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Non-prostanoid thromboxane A2 receptor antagonists with a dibenzoxepin ring system. 1.
AID232744Selectivity index for the difference between the IC50 values in the aggregation and contraction assay1993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
Design, synthesis, and pharmacology of 3-substituted sodium azulene-1-sulfonates and related compounds: non-prostanoid thromboxane A2 receptor antagonists.
AID210336Tested in vitro for percent inhibition against TXA2 / PGH-2 receptor using [125I]PTA-OH in human platelets at 10 e-7 M1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Synthesis and structure-activity relationships of novel benzimidazole and imidazo[4,5-b]pyridine acid derivatives as thromboxane A2 receptor antagonists.
AID212257Inhibition of the thromboxane A2 receptor assayed by binding to guinea pig platelets using [3H]U-46619 as radioligand1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Non-prostanoid thromboxane A2 receptor antagonists with a dibenzoxepin ring system. 1.
AID176487Compound concentration inhibiting 48 hr homologous passive cutaneous Anaphylaxis in rats peroral administration; No efficacy1993Journal of medicinal chemistry, Feb-05, Volume: 36, Issue:3
Dibenz[b,e]oxepin derivatives: novel antiallergic agents possessing thromboxane A2 and histamine H1 dual antagonizing activity. 1.
AID222769Inhibition of platelet aggregation induced by arachidonic acid(AA) in human platelet-rich plasma1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Synthesis and pharmacological evaluation of 5,6-exo-epoxy-7-oxabicyclo[2.2.1]heptane derivatives.
AID76460Inhibitory effect of the compounds on U-46619-induced platelet aggregation ex vivo in guinea pig at the dose of 100 mg/kg 2 hr after oral administration1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Non-prostanoid thromboxane A2 receptor antagonists with a dibenzoxepin ring system. 1.
AID167793Compound was tested for the inhibition U-46619 (3 x10 E -8 M) induced vascular contraction (TXA2 tao receptor) in rabbit thoracic aorta1993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
Design, synthesis, and pharmacology of 3-substituted sodium azulene-1-sulfonates and related compounds: non-prostanoid thromboxane A2 receptor antagonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (139)

TimeframeStudies, This Drug (%)All Drugs %
pre-199066 (47.48)18.7374
1990's65 (46.76)18.2507
2000's6 (4.32)29.6817
2010's2 (1.44)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.61 (24.57)
Research Supply Index5.06 (2.92)
Research Growth Index4.08 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials12 (8.33%)5.53%
Reviews3 (2.08%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other129 (89.58%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]